eGPA and Local Inflammation Within the Ear, Nose and Throat Area

Condition(s) studied

Investigational drug(s) / intervention(s)

laboratory experiments before and after mepolizumab treatment: Patients that start with mepolizumab treatment on the basis of the clinical disease course will be measured prior and after start of mepolizumab to evaluate the effects this medication has on various immunological parameters and microbiome

Study summary

Rationale: Eosinophilic Granulomatosis with Polyangiitis (eGPA), eosinophilic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) are airway diseases where eosinophils and interleukine-5 are involved in the pathogenesis. eGPA differs from the other diseases with respect to involvement of other organs. The investigators hypothesize that nasal microbiome dysbiosis with a central augmenting role for S. Aureus plays an important role in disease expression. The investigators expect that anti-interleukin-5 treatment with mepolizumab restores the changes of the nasal microbiome and immune responses to a healthy control phenotype. To study this, the nasal microbiome, the local and systemic immune response and the effect of mepolizumab treatment will be assessed.

Eligibility

Primary outcome measure(s)

• The effect mepolizumab treatment has on the nasal microbiome profiles — three months
  Paired change in microbiome diversity index for patients treated with mepolizumab.

Trial sites (1)

More University Medical Center Groningen trials in the Netherlands